Department of Error  by unknown
Correspondence
958 www.thelancet.com   Vol 376   September 18, 2010
reason that our report stated the 
need for extensive genotyping of 
APOA5 (and related loci) in relation 
to detailed lipoprotein assessments 
(such as those based on structural 
and functional characteristics).
Jean Dallongeville and Aline 
Meirhaeghe suggest that caution 
should be exercised in interpreting our 
study because the results might not 
necessarily indicate a role for hyper-
triglyceridaemia itself, especially since 
triglyceride metabolism is modulated 
by factors such as diabetes, obesity, 
and smoking. It was due to such 
considerations that the title and 
conclusions of our report related to 
“triglyceride-mediated pathways” 
rather than to hypertriglyceridaemia. 
(Our study showed that the APOA5 
–1131T>C genotype is not materially 
correlated to the prevalence of diabetes, 
obesity, and smoking.)
Di Zeng and colleagues describe 
potential limitations of genetic 
association studies, including the 
possibility of confounding by other 
genetic loci, unrecognised gene–
environmental interactions, and 
developmental compensation. We 
anticipated such potential limitations 
in our paper, stating, for example, 
that future studies should aim to 
include several (unlinked) genetic 
variants as deconfounding tools, 
because if they produce congruent 
predictions to those in our report, the 
scope for such confounding would 
be reduced.
As stated in our report, our study’s 
main limitation was lack of access 
to individual participant data for 
the genetic component, which is 
now being addressed in a further 
collaborative investigation.
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Drug manufacturing 
in Africa
Tatum Anderson (May 8, p 1597)1 
highlights important elements of the 
debate surrounding local pharma-
ceutical production in developing 
countries. But some of her points 
relating to the WHO Prequaliﬁ cation 
of Medicines Programme (WHO/
PQP) lack nuance and detail.
WHO/PQP does indeed do a 
“stringent quality check” of any 
medicinal product submitted to it for 
assessment. However, the check is not 
“imposed” but part of a process that 
manufacturers undergo voluntarily 
and at no cost to themselves.
Analysis of sampling and testing 
results for antimalarials indicates that 
prequaliﬁ cation by WHO is a strong 
indicator of a medicine’s quality. In a 
study funded by the European Union 
(as yet unpublished), 935 samples 
were collected in 2008 in Cameroon, 
Ethiopia, Ghana, Kenya, Nigeria, and 
Tanzania. Quality-control laboratories 
tested about 30% of the samples. 
Only three (3·6%) of the 83 samples 
of WHO-pre qualiﬁ ed antimalarials 
deviated from prespeciﬁ ed quality 
criteria, compared with 73 (39·7%) 
of the 184 samples of non-WHO-
prequaliﬁ ed antimalarials.
The study also compared the results 
of minilabs used to screen medicines 
in the ﬁ eld with those of quality-
control laboratories. The quality-
control laboratories identiﬁ ed a 
greater number of poor-quality 
antimalarials than did the minilabs. 
WHO/PQP has so far prequaliﬁ ed 
14 quality-control laboratories, and a 
further 30 (16 in sub-Saharan Africa) 
are working towards prequaliﬁ cation. 
Anderson mentions the eﬀ orts of 
Deutsche Gesellschaft für Technische 
Zusammenarbeit (GTZ) to help 
African manufacturers identify the 
improve ments necessary to reach 
international standards, but not 
similar eﬀ orts undertaken by WHO/
PQP. In fact, WHO/PQP works with 
many national regulatory authorities, 
quality-control laboratories, and 
manufacturers, in numerous de-
veloping countries, to help them 
acquire the skills needed for ensuring 
medicines quality.
Local manufacturing in Africa 
re mains a diﬃ  cult issue since 
compliance with international stan-
dards within Africa varies signi-
ﬁ cantly. But WHO/PQP targets 
resources and eﬀ orts to boost both 
the quality of that production, 
and the capacity to ensure that it 
is monitored and maintained. We 
believe that our eﬀ orts, combined 
with those of many other parties, 
can contribute to better medicines 
for Africa. Our aspiration, however, 
is that any local pharmaceutical 
production, independent of its 
location, meets quality standards.
We declare that we have no conﬂ icts of interest.
Lembit Rägo, Jitka Sabartova, 
*Jacqueline Sawyer
sawyerj@who.int
Department of Essential Medicines and 
Pharmaceutical Policies, World Health 
Organization, 1211 Geneva 27, Switzerland
1 Anderson T. Tide turns for drug 
manufacturing in Africa. Lancet 2010; 
375: 1597–98.
Department of Error
The Emerging Risk Factors Collaboration. 
Diabetes mellitus, fasting blood glucose 
concentration, and risk of vascular disease: a 
collaborative meta-analysis of 102 prospective 
studies. Lancet 2010; 375: 2215–22—In the 
investigator list of this Article, “H L Hillage” 
(PREVEND study) should have read 
“H L Hillege”. This correction has been made 
to the online version as of Sept 17, 2010.
Maczyczka A, Squire IB. Cough syncope—
a diagnosis under pressure. Lancet 2010; 
376: 486—In this Case Report (Aug 7), the 
ﬁ rst author’s surname was mis-spelled. The 
correct spelling is “Maznyczka”. This 
correction has been made to the online 
version as of Sept 17, 2010.
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